Carcinoma, Hepatocellular
Showing NaN - NaN of 22
Carcinoma, Hepatocellular Trial in Worldwide (drug, biological, procedure)
Active, not recruiting
- Carcinoma, Hepatocellular
- Lenvatinib
- +4 more
-
Tucson, Arizona
- +206 more
Jan 31, 2023
Carcinoma, Hepatocellular Trial in China, Korea, Republic of, Taiwan (Tepotinib 300 mg, Tepotinib 500 mg, Tepotinib 1000 mg)
Completed
- Carcinoma, Hepatocellular
- Tepotinib 300 mg
- +4 more
-
Beijing, Beijing, China
- +42 more
Aug 22, 2022
Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab, Sorafenib)
Active, not recruiting
- Carcinoma, Hepatocellular
- Atezolizumab
- +2 more
-
Phoenix, Arizona
- +118 more
Jun 14, 2022
Carcinoma, Hepatocellular Trial in Worldwide (biological, drug, other)
Active, not recruiting
- Carcinoma, Hepatocellular
- pembrolizumab
- +2 more
-
Hefei, Anhui, China
- +40 more
Mar 3, 2022
Carcinoma, Hepatocellular Trial in Worldwide (Refametinib (BAY86-9766), Sorafenib (BAY43-9006))
Completed
- Carcinoma, Hepatocellular
- Refametinib (BAY86-9766)
- Sorafenib (BAY43-9006)
-
Louisville, Kentucky
- +78 more
Apr 6, 2021
Carcinoma, Hepatocellular Trial in Worldwide (Refametinib (BAY86-9766))
Completed
- Carcinoma, Hepatocellular
- Refametinib (BAY86-9766)
-
Washington, District of Columbia
- +57 more
Apr 6, 2021
Carcinoma, Hepatocellular Trial in Taiwan (Atezolizumab, Bevacizumab)
Recruiting
- Carcinoma, Hepatocellular
-
Kaohsiung, Taiwan
- +7 more
Mar 26, 2021
Carcinoma, Hepatocellular Trial in China, Korea, Republic of, Taiwan (JNJ-42756493 (erdafitinib))
Completed
- Carcinoma, Hepatocellular
- JNJ-42756493 (erdafitinib)
-
Changchun, China
- +9 more
Feb 17, 2020
Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva), Placebo)
Completed
- Carcinoma, Hepatocellular
- Sorafenib (Nexavar, BAY43-9006)
- +2 more
-
San Francisco, California
- +126 more
May 16, 2019
Carcinoma, Hepatocellular Trial in Tainan, Taipei, Taoyuan City (Ramucirumab, FOLFOX4)
Carcinoma, Hepatocellular Trial in Worldwide (Nexavar (Sorafenib, BAY43-9006), Placebo)
Completed
- Carcinoma, Hepatocellular
- Nexavar (Sorafenib, BAY43-9006)
- Placebo
-
Birmingham, Alabama
- +198 more
Jul 11, 2018
Carcinoma, Hepatocellular Trial in China, Taiwan, Thailand (Capecitabine, Peginterferon alfa-2a)
Completed
- Carcinoma, Hepatocellular
- Capecitabine
- Peginterferon alfa-2a
-
Beijing, China
- +7 more
Nov 1, 2016
Carcinoma, Hepatocellular Trial in Tainan, Taipei, Taoyuan (Vandetanib, Best Supportive Care)
Completed
- Carcinoma, Hepatocellular
- Vandetanib
- Best Supportive Care
-
Tainan, Taiwan
- +2 more
Aug 29, 2016
Carcinoma, Hepatocellular Trial in Korea, Republic of, Taiwan (Sorafenib, BIBF 1120)
Completed
- Carcinoma, Hepatocellular
- Sorafenib
- BIBF 1120
-
Seoul, Korea, Republic of
- +15 more
Feb 9, 2016
Carcinoma, Hepatocellular Trial in China, Korea, Republic of, Taiwan (Sorafenib (Nexavar, BAY43-9006), Placebo)
Completed
- Carcinoma, Hepatocellular
- Sorafenib (Nexavar, BAY43-9006)
- Placebo
-
Hefei, Anhui, China
- +22 more
Mar 26, 2014
Carcinoma, Hepatocellular Trial in Worldwide (BAY86-9766 MEK Inhibitor + Sorafenib)
Completed
- Carcinoma, Hepatocellular
- BAY86-9766 MEK Inhibitor + Sorafenib
-
Shatin, New Territories, Hong Kong
- +14 more
Sep 5, 2013
Carcinoma, Hepatocellular Trial in Worldwide (sunitinib malate, sorafenib)
Terminated
- Carcinoma, Hepatocellular
- sunitinib malate
- sorafenib
-
Fountain Valley, California
- +170 more
Dec 7, 2012